Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

High-dose interleukin-2 and interferon as first-line immunotherapy for metastatic melanoma: long-term follow-up in a large unselected Danish patient cohort

Research output: Contribution to journalJournal articleResearchpeer-review

  1. The real-world impact of modern treatments on the survival of patients with metastatic melanoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Establishing the European Norm for the health-related quality of life domains of the computer-adaptive test EORTC CAT Core

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. The EORTC CAT Core-The computer adaptive version of the EORTC QLQ-C30 questionnaire

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Peripheral memory T cells specific for Arginase-1

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Empty peptide-receptive MHC class I molecules for efficient detection of antigen-specific T cells

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Real-world evidence to guide healthcare policies in oncology

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. undersøges !!

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND AND PATIENTS: Between January 2007 and April 2014, 464 Danish patients received high-dose (HD) interleukin-2 (IL-2) and interferon (IFN) as first-line treatment for metastatic melanoma. Our data represent the largest cohort of patients with metastatic melanoma worldwide, with relevant data on all patients and no patients lost to follow-up. Data have been gathered in a national database on the treatment of metastatic melanoma established since 2011.

RESULTS: One hundred eighteen patients (25%) obtained an objective response rate (ORR) to treatment with a median progression-free survival (PFS) of 3.4 months and a median overall survival (OS) of 14.2 months. Furthermore, 2-, 3- and 5-year survival was 32.0%, 23.2% and 16.6%, respectively. Ipilimumab as second-line therapy has been used since July 2010. We divided patients in two subgroups before and after this date to evaluate the effects of new treatment strategies. Patient characteristics, ORR and PFS were comparable in the two subgroups. Survival was significantly improved after 2010, with an increase in median OS from 12.2 to 16.0 months and in 5-year OS from 12.5% to 20.7%.

CONCLUSIONS: Our data confirm that HD IL-2/IFN as first-line therapy in metastatic melanoma leads to long-term survival in a subset of treated patients. Potentially, IL-2/IFN might represent a treatment option in patients with active melanoma after established initial treatment with checkpoint inhibitors and BRAF/MEK-targeted therapies.

Original languageEnglish
JournalEuropean journal of cancer (Oxford, England : 1990)
Volume115
Pages (from-to)61-67
Number of pages7
ISSN0959-8049
DOIs
Publication statusPublished - Jul 2019

ID: 57729215